These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 38261390)

  • 21. Health-related quality of life, remission and low lupus disease activity state in patients with systemic lupus erythematosus.
    Thibault T; Rajillah A; Bourredjem A; Corneloup M; Maurier F; Wahl D; Muller G; Aumaitre O; Sève P; Blaison G; Besancenot JF; Martin T; Magy-Bertrand N; Samson M; Arnaud L; Amoura Z; Devilliers H;
    Rheumatology (Oxford); 2024 May; 63(5):1447-1455. PubMed ID: 37589711
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Failure to achieve lupus low disease activity state (LLDAS) six months after diagnosis is associated with early damage accrual in Caucasian patients with systemic lupus erythematosus.
    Piga M; Floris A; Cappellazzo G; Chessa E; Congia M; Mathieu A; Cauli A
    Arthritis Res Ther; 2017 Nov; 19(1):247. PubMed ID: 29126432
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Molecular characterisation of lupus low disease activity state (LLDAS) and DORIS remission by whole-blood transcriptome-based pathways in a pan-European systemic lupus erythematosus cohort.
    Parodis I; Lindblom J; Barturen G; Ortega-Castro R; Cervera R; Pers JO; Genre F; Hiepe F; Gerosa M; Kovács L; De Langhe E; Piantoni S; Stummvoll G; Vasconcelos C; Vigone B; Witte T; ; Alarcón-Riquelme ME; Beretta L
    Ann Rheum Dis; 2024 Jun; 83(7):889-900. PubMed ID: 38373843
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Glucocorticoid withdrawal in systemic lupus erythematosus: are remission and low disease activity reliable starting points for stopping treatment? A real-life experience.
    Tani C; Elefante E; Signorini V; Zucchi D; Lorenzoni V; Carli L; Stagnaro C; Ferro F; Mosca M
    RMD Open; 2019; 5(2):e000916. PubMed ID: 31275608
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Development of the Asia Pacific Lupus Collaboration cohort.
    Kandane-Rathnayake R; Golder V; Louthrenoo W; Luo SF; Jan Wu YJ; Li Z; An Y; Lateef A; Sockalingam S; Navarra SV; Zamora L; Hamijoyo L; Katsumata Y; Harigai M; Chan M; O'Neill S; Goldblatt F; Hao Y; Zhang Z; Al-Saleh J; Khamashta M; Takeuchi T; Tanaka Y; Bae SC; Lau CS; Hoi A; Nikpour M; Morand EF
    Int J Rheum Dis; 2019 Mar; 22(3):425-433. PubMed ID: 30398013
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Frequency and predictors for early-achieved lupus low disease activity state in systemic lupus erythematosus patients treated with telitacicept or belimumab: A real-life, single-center observational study.
    Fan C; Yang T; Zheng S; Liao X; Xie R; Chen S; Li J
    Front Immunol; 2024; 15():1423035. PubMed ID: 38947321
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Determinants and protective associations of the lupus low disease activity state in a prospective Chinese cohort.
    Hao Y; Oon S; Ji L; Gao D; Fan Y; Geng Y; Zhang X; Li G; Morand EF; Nikpour M; Zhang Z
    Clin Rheumatol; 2022 Feb; 41(2):357-366. PubMed ID: 34595670
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Disease-modifying effect and long-term safety of belimumab in patients with systemic lupus erythematosus: A single-center retrospective study.
    Nakai T; Fukui S; Sawada H; Ikada Y; Tamaki H; Kishimoto M; Okada M
    Lupus; 2023 Nov; 32(13):1518-1527. PubMed ID: 37858981
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Low disease activity and remission status of systemic lupus erythematosus in a real-world study].
    Ren L; Zhao C; Zhao Y; Zhou H; Zhang L; Wang Y; Shen L; Fan W; Li Y; Li X; Wang J; Cheng Y; Peng J; Zhao X; Shao M; Li R
    Beijing Da Xue Xue Bao Yi Xue Ban; 2024 Apr; 56(2):273-278. PubMed ID: 38595244
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Lupus Low Disease Activity State and Reduced Direct Health Care Costs in Patients With Systemic Lupus Erythematosus.
    Yeo AL; Koelmeyer R; Kandane-Rathnayake R; Golder V; Hoi A; Huq M; Hammond E; Nab H; Nikpour M; Morand EF
    Arthritis Care Res (Hoboken); 2020 Sep; 72(9):1289-1295. PubMed ID: 31282076
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Association of glucocorticoid doses and emotional health in lupus low disease activity state (LLDAS): a cross-sectional study.
    Miyawaki Y; Shimizu S; Ogawa Y; Sada KE; Katayama Y; Asano Y; Hayashi K; Yamamura Y; Hiramatsu-Asano S; Ohashi K; Morishita M; Watanabe H; Takano-Narazaki M; Matsumoto Y; Yajima N; Yoshimi R; Shimojima Y; Ohno S; Kajiyama H; Ichinose K; Sato S; Fujiwara M; Yamazaki H; Yamamoto Y; Wada J; Fukuhara S
    Arthritis Res Ther; 2021 Mar; 23(1):79. PubMed ID: 33691746
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Targeting DORIS Remission and LLDAS in SLE: A Review.
    Parra Sánchez AR; van Vollenhoven RF; Morand EF; Bruce IN; Kandane-Rathnayake R; Weiss G; Tummala R; Al-Mossawi H; Sorrentino A
    Rheumatol Ther; 2023 Dec; 10(6):1459-1477. PubMed ID: 37798595
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Association of the lupus low disease activity state (LLDAS) with health-related quality of life in a multinational prospective study.
    Golder V; Kandane-Rathnayake R; Hoi AY; Huq M; Louthrenoo W; An Y; Li ZG; Luo SF; Sockalingam S; Lau CS; Mok MY; Lateef A; Franklyn K; Morton S; Navarra ST; Zamora L; Wu YJ; Hamijoyo L; Chan M; O'Neill S; Goldblatt F; Nikpour M; Morand EF;
    Arthritis Res Ther; 2017 Mar; 19(1):62. PubMed ID: 28320433
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pragmatic targets for moderate/severe SLE and their implications for clinical care and trial design: sustained DORIS or LLDAS for at least 6 months is sufficient while their attainment for at least 24 months ensures high specificity for damage-free progression.
    Pitsigavdaki S; Nikoloudaki M; Garantziotis P; Silvagni E; Repa A; Marangoni A; Flouri I; Avgoustidis N; Parperis K; Fanouriakis A; Govoni M; Sidiropoulos P; Boumpas DT; Bortoluzzi A; Bertsias G
    Ann Rheum Dis; 2024 Mar; 83(4):464-474. PubMed ID: 38233103
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Lupus low disease activity state attainment in the phase 3 TULIP trials of anifrolumab in active systemic lupus erythematosus.
    Morand EF; Abreu G; Furie RA; Golder V; Tummala R
    Ann Rheum Dis; 2023 May; 82(5):639-645. PubMed ID: 36690388
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Frequency and predictors of the lupus low disease activity state in a multi-national and multi-ethnic cohort.
    Golder V; Kandane-Rathnayake R; Hoi AY; Huq M; Louthrenoo W; An Y; Li ZG; Luo SF; Sockalingam S; Lau CS; Lee AL; Mok MY; Lateef A; Franklyn K; Morton S; Navarra ST; Zamora L; Wu YJ; Hamijoyo L; Chan M; O'Neill S; Goldblatt F; Morand EF; Nikpour M;
    Arthritis Res Ther; 2016 Nov; 18(1):260. PubMed ID: 27829463
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Time to Lupus Low Disease Activity State in the Hopkins Lupus Cohort: Role of African American Ethnicity.
    Babaoğlu H; Li J; Goldman D; Magder LS; Petri M
    Arthritis Care Res (Hoboken); 2020 Feb; 72(2):225-232. PubMed ID: 31507071
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Articular involvement, steroid treatment and fibromyalgia are the main determinants of patient-physician discordance in systemic lupus erythematosus.
    Elefante E; Tani C; Stagnaro C; Signorini V; Parma A; Carli L; Zucchi D; Ferro F; Mosca M
    Arthritis Res Ther; 2020 Oct; 22(1):241. PubMed ID: 33054823
    [TBL] [Abstract][Full Text] [Related]  

  • 39. LUPUS-BEST-treat-to-target in systemic lupus erythematosus: study protocol for a three-armed cluster-randomised trial.
    Mucke J; Kuss O; Brinks R; Schanze S; Schneider M
    Lupus Sci Med; 2021 Jul; 8(1):. PubMed ID: 34253649
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Lupus low disease activity state within 12 months is associated with favourable outcomes in severely active systemic lupus erythematosus.
    Kikuchi J; Hanaoka H; Saito S; Oshige T; Hiramoto K; Kaneko Y; Takeuchi T
    Rheumatology (Oxford); 2022 Aug; 61(9):3777-3791. PubMed ID: 35015824
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.